Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose 5% provides a source of calories and hydration; sodium chloride 0.45% provides electrolytes and maintains osmotic balance. Dextrose is metabolized to carbon dioxide and water, yielding energy. Sodium chloride dissociates to maintain extracellular fluid volume and osmolality.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Fluid and electrolyte replacement,Treatment of dehydration,Maintenance of hydration and caloric supply in patients unable to take oral fluids,Diluent for compatible medications
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous administration; typical adult dose is 1000-2000 m L over 24 hours, rate adjusted based on patient's fluid and electrolyte status. Maximum infusion rate is 1000 m L per hour.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Dextrose: not applicable as it is rapidly metabolized; the half-life of infused glucose is approximately 1.5-2 hours in healthy individuals, but prolonged in conditions like diabetes. Sodium: biological half-life is 10-20 hours, depending on fluid balance and renal function.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Dextrose undergoes glycolysis and subsequent oxidation via the citric acid cycle. Sodium chloride is not metabolized; it is excreted unchanged by the kidneys.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Dextrose is metabolized to carbon dioxide and water, with negligible renal excretion of intact dextrose under normal conditions. Sodium and chloride are primarily excreted renally; sodium excretion is regulated by glomerular filtration and tubular reabsorption, while chloride follows sodium. In patients with normal renal function, >90% of infused sodium and chloride are excreted in urine within 24-48 hours.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Dextrose: negligible binding to plasma proteins. Sodium: minimal binding (approx. 0-10%) to albumin and other proteins. Chloride: not significantly protein bound.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Dextrose: distributes into total body water, approximately 0.55-0.65 L/kg (based on 60% of body weight as water in adults). Sodium: distributes into extracellular fluid, approximately 0.20-0.25 L/kg. Chloride: similar to sodium, extracellular fluid, approximately 0.20 L/kg.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intravenous: 100% for all components.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
For GFR < 10 m L/min: reduce to 50% of standard dose or avoid due to risk of volume overload and hypernatremia; monitor closely for signs of fluid overload and electrolyte disturbances.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
Not required: no dose adjustment needed for hepatic impairment.
No dosage adjustment required for hepatic impairment.
Intravenous; dose based on daily maintenance fluid requirements: 0-10 kg: 100 m L/kg/day; 10-20 kg: 1000 m L + 50 m L/kg for each kg over 10; >20 kg: 1500 m L + 20 m L/kg for each kg over 20. Infusion rate adjusted to patient's clinical status.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Use with caution: lower initial doses and slower infusion rates recommended to avoid fluid overload; monitor renal function and electrolyte balance.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
None
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Use with caution in patients with congestive heart failure, renal impairment, or hyperglycemia,Monitor serum glucose, electrolytes, and fluid status,Risk of hyperglycemia and hyperosmolar syndrome in patients with diabetes mellitus or stress-induced insulin resistance,Not for use in patients with intracranial or intraspinal hemorrhage or in patients who are comatose with hyperglycemia
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hyperglycemia,Hypersensitivity to any component,Severe electrolyte abnormalities (e.g., hypernatremia),Patients with known allergies to corn or corn products (dextrose derived from corn)
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
Avoid excessive intake of high-sodium foods such as processed snacks, canned soups, and fast foods to prevent exacerbation of sodium overload. No specific food interactions with dextrose; however, diabetic patients should monitor carbohydrate intake and adjust insulin accordingly. Alcohol may impair glucose metabolism and enhance hypoglycemia risk; avoid or limit consumption.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
No known teratogenic risk. Dextrose and sodium chloride are physiologic substances. In trimester 1, no increased risk of major malformations. In trimesters 2 and 3, use is safe when indicated for maternal hydration or electrolyte balance; avoid excessive dextrose causing maternal hyperglycemia which can lead to fetal hyperinsulinism and neonatal hypoglycemia.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Excreted into breast milk in small amounts; M/P ratio not clinically relevant. Dextrose and sodium chloride are normal milk components. Considered compatible with breastfeeding; monitor infant for signs of electrolyte imbalance if high doses administered to mother.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
No dose adjustment required for dextrose 5% and sodium chloride 0.45% in pregnancy. However, pregnant women have increased plasma volume; consider monitoring for fluid overload in conditions like preeclampsia. Insulin resistance may require glucose monitoring if large volumes are infused.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
This isotonic solution (D5 0.45% Na Cl) provides 170 kcal/L as dextrose and 77 m Eq/L sodium, 77 m Eq/L chloride. Use cautiously in patients with hyponatremia or sodium retention (heart failure, cirrhosis, renal impairment). Monitor serum glucose in diabetic patients; may cause hyperglycemia. Not suitable for resuscitation due to low sodium content. Avoid in patients with known allergy to corn-derived dextrose.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Report any shortness of breath, swelling in legs, or rapid weight gain, as these may indicate fluid overload.,Inform your healthcare provider if you have diabetes, as this solution contains sugar and may affect blood glucose levels.,Tell your doctor if you have a history of kidney problems, heart failure, or high blood pressure.,Do not consume extra salt or salty foods without consulting your doctor.,Notify your nurse immediately if you experience pain, redness, or swelling at the infusion site.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.45% vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% is a Electrolyte that works by Dextrose 5% provides a source of calories and hydration; sodium chloride 0.45% provides electrolytes and maintains osmotic balance. Dextrose is metabolized to carbon dioxide and water, yielding energy. Sodium chloride dissociates to maintain extracellular fluid volume and osmolality.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.45% and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.45% is: Intravenous administration; typical adult dose is 1000-2000 m L over 24 hours, rate adjusted based on patient's fluid and electrolyte status. Maximum infusion rate is 1000 m L per hour.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.45% and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.45% is classified as Category A/B. No known teratogenic risk. Dextrose and sodium chloride are physiologic substances. In trimester 1, no increased risk of major malformations. In trimesters 2 and 3, use is safe whe. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.